Φορτώνει......

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Despite being considered “good-risk” acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) a...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Am J Hematol
Κύριοι συγγραφείς:	Borthakur, Gautam, Cortes, Jorge E., Estey, Elihu E., Jabbour, Elias, Faderl, Stefan, O’Brien, Susan, Garcia-Manero, Guillermo, Kadia, Tapan Mahendra, Wang, Xuemei, Patel, Keyur, Luthra, Rajyalakshmi, Koller, Charles, Brandt, Mark, Ravandi, Farhad, Kantarjian, Hagop
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	2014
Θέματα:	Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4431614/ https://ncbi.nlm.nih.gov/pubmed/24990142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23795
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Παρόμοια τεκμήρια